Summary

Report Overview
The Global Cancer Tumor Profiling Market reached US$ 9.5 billion in 2023 and is expected to reach US$ 19.15 billion by 2031, growing at a CAGR of 9.4% during the forecast period 2024-2031.
Tumor profiling is a laboratory test to check for gene mutations or other alterations that make up the tumor biology and underlie the cancer growth. This information can help physicians build a personalized treatment plan based on the tumor profile. Tumor profiling is the technology oncologists use to determine if the pathways of a patient’s tumor match up with available targeted treatments. Tumor profiling allows for deep analysis of a tumor’s molecular characteristics that are responsible for cancer progression and therapy resistance. 
Tumor profiling, also known as biomarker testing, is a detailed and sensitive laboratory analysis of cancer cells. The purpose of this testing expose specific biomarker mutations and identify targeted therapies matched to any found mutations. Tumor profiling can help guide and identify the most effective treatment plan. Tumor profiling starts with obtaining a sample of tumor tissue. The tissue is usually collected through a core biopsy.
Market Dynamics: Drivers
Increasing prevalence of cancer
The demand for the global cancer tumor profiling market is driven by multiple factors. The rising prevalence of cancers propels the market growth. For instance, according to an article published by nih.gov in January 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. Cancer incidence increased for prostate cancer by 3% annually from 2014 through 2019 after two decades of decline, translating to an additional 99,000 new cases. 
Moreover, according to wcrf.org, including non-melanoma skin cancer (NMSC) there were 19,976,499 cancer cases in 2022. When NMSC was excluded, this number dropped to 18,741,966 cancer cases around the world in 2022. Of these, 9,566,825 were in men and 9,175,141 in women. Moreover, according to IARC, There were close to 20 million new cases of cancer in the year 2022 (including nonmelanoma skin cancers [NMSCs]) alongside 9.7 million deaths from cancer (including NMSC). The estimates suggest that approximately one in five men or women develop cancer in a lifetime, whereas around one in nine men and one in 12 women die from it. Lung cancer was the most frequently diagnosed cancer in 2022, responsible for almost 2.5 million new cases, or one in eight cancers worldwide (12.4% of all cancers globally).
Restraints
Factors such as high cost associated with the procedure, lack of healthcare infrastructure, lack of reimbursement policies, and technical issues in sample collection and storage conditions are expected to hamper the market.
Market Segment Analysis
The global cancer tumor profiling market is segmented based on cancer type, technology type, biomarker type, application, end-user, and region.
The segment next-generation sequencing accounted for approximately 48.9% of the global cancer tumor profiling market share
The next-generation sequencing segment is expected to hold the largest market share over the forecast period. In this segment, technological advancements would drive this market. 
Next-generation sequencing (NGS), also known as massively parallel sequencing, represents an effective way to capture a large amount of genomic information about a cancer. Most NGS technologies revolve around sequencing by synthesis. Each DNA fragment to be sequenced is bound to an array, and then DNA polymerase adds labeled nucleotides sequentially. A high-resolution camera captures the signal from each nucleotide becoming integrated and notes the spatial coordinates and time. The sequence at each spot can then be inferred by a computer program to generate a contiguous DNA sequence, referred to as a read.
For instance, in April 2023, Agilent Technologies Inc. announced the launch of the Agilent SureSelect Cancer CGP Assay designed for somatic variant profiling for a broad range of solid tumor types. The pan-cancer assay design is based on an NGS panel comprising 679 genes globally curated from leading cancer databases and in partnership with key clinical cancer researchers.
Market Geographical Analysis
North America accounted for approximately 43.6% of the global cancer tumor profiling market share 
North America region is expected to hold the largest market share over the forecast period. The rising incidence of cancer, and technological advancements, in this region, help to propel the market. 
For instance, according to an article published by nih.gov in January 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States. Cancer mortality continued to decline through 2021, averting over 4 million deaths since 1991 because of reductions in smoking, earlier detection for some cancers, and improved treatment options in both adjuvant and metastatic settings. However, these gains are threatened by increasing incidence for 6 of the top 10 cancers.
Moreover, in September 2023, Pillar Biosciences, Inc., the leader in Decision Medicine, announced the global launch of oncoReveal Core LBx, a research-use-only (RUO) next-generation sequencing (NGS) kit designed to enable laboratories with a solution for liquid biopsy-based pan-cancer tumor profiling.
Market Segmentation
By Cancer Type
Lung Cancer
Prostate Cancer
Breast Cancer
Colorectal Cancer
Melanoma cancer
Others 
By Technology Type
Immunoassays
Next-Generation Sequencing
Polymerase Chain Reaction
In-Situ Hybridization
Microarray
Others
By Biomarker Type
Genomics Biomarker
Protein Biomarker
Others
By Application
Research Applications
Clinical Applications
Diagnostics
Personalized Medicines
Others
By End-User
Hospitals
Diagnostic Centers
Research and Academic Institutions
Others
By Region
North America 
U.S.
Canada
Mexico
Europe 
Germany
U.K.
France
Spain
Italy
Rest of Europe 
South America 
Brazil
Argentina
Rest of South America
Asia-Pacific 
China
India
Japan
South Korea
Rest of Asia-Pacific 
Middle East and Africa
Market Competitive Landscape
The major global players in the global cancer tumor profiling market include Qiagen N.V, NeoGenomics Laboratories, Genomic Health Inc., Caris Life Sciences, Helomics Corporation, NanoString Technologies Inc., Sysmex Corporation, Ribomed Biotechnologies Inc., Roche Diagnostics and Illumina Inc. among others.
Key Developments
In May 2024, Foundation Medicine Inc. announced the U.S. launch of FoundationOne®RNA, a tissue-based RNA sequencing test for the detection of cancer-related fusions across 318 genes. FoundationOne RNA enables reporting of fusions in all solid tumors and may be valuable for detecting fusions in certain cancers, such as non-small cell lung cancer (NSCLC), pancreatic cancer, cholangiocarcinoma, sarcoma, thyroid cancer, and bladder cancer. 
In November 2023, Illumina Inc. announced a new generation of its distributed liquid biopsy assay for genomic profiling. The new TruSight™ Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that enables noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood when tissue testing is not available or to complement tissue-based testing.
Why Purchase the Report?
To visualize the global cancer tumor profiling market segmentation based on cancer type, technology type, biomarker type, application, end-user, and region, as well as understand key commercial assets and players. 
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of global cancer tumor profiling market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The global cancer tumor profiling market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Cancer Type
3.2. Snippet by Technology Type
3.3. Snippet by Biomarker Type
3.4. Snippet by Application
3.5. Snippet by End-User
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Cancer
4.1.1.2. Technological Advancements
4.1.1.3. Government Initiatives and Fundings
4.1.2. Restraints
4.1.2.1. High Costs of Procedure
4.1.2.2. Lack of Healthcare Infrastructure
4.1.2.3. Lack of Reimbursement Policies
4.1.2.4. Technical Issues in Collecting Samples
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Cancer Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
6.1.2. Market Attractiveness Index, By Cancer Type
6.2. Lung Cancer*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Prostate Cancer
6.4. Breast Cancer
6.5. Colorectal Cancer
6.6. Melanoma Cancer
6.7. Others
7. By Technology Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
7.1.2. Market Attractiveness Index, By Technology Type
7.2. Immunoassays*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Next-Generation Sequencing
7.4. Polymerase Chain Reaction
7.5. In-Situ Hybridization
7.6. Microarray
7.7. Others
8. By Biomarker Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
8.1.2. Market Attractiveness Index, By Biomarker Type
8.2. Genomics Biomarker*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Protein Biomarker
8.4. Others
9. By Application
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index, By Application
9.2. Research Applications*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Clinical Applications
9.4. Diagnostics
9.5. Personalized Medicines
9.6. Others
10. By End-User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Diagnostic Centers
10.4. Research and Educational Institutions
10.5. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.8.1. The U.S.
11.2.8.2. Canada
11.2.8.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.8.1. Germany
11.3.8.2. UK
11.3.8.3. France
11.3.8.4. Italy
11.3.8.5. Spain
11.3.8.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.8.1. Brazil
11.4.8.2. Argentina
11.4.8.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.8.1. China
11.5.8.2. India
11.5.8.3. Japan
11.5.8.4. South Korea
11.5.8.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Qiagen N.V *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. NeoGenomics Laboratories
13.3. Genomic Health Inc.
13.4. Caris Life Sciences
13.5. Helomics Corporation
13.6. NanoString Technologies
13.7. Sysmex Corporation
13.8. Ribomed Biotechnologies Inc.
13.9. Roche Diagnostics
13.10. Illumina Inc. (*LIST NOT EXHAUSTIVE)
14. Appendix
14.1. About Us and Services
14.2. Contact Us